In rasmussen encephalitis, hemichannels associated with microglial activation are linked to cortical pyramidal neuron coupling: A possible mechanism for cellular hyperexcitability

CNS Neuroscience and Therapeutics

Volumn 21, Issue 2, 2015, Pages 152-163

  Cepeda, Carlos ^a   Chang, Julia W ^b   Owens, Geoffrey C ^b   Huynh, My N ^b   Chen, Jane Y ^a   Tran, Conny ^a   Vinters, Harry V ^b   Levine, Michael S ^a   Mathern, Gary W ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MATTEL CHILDREN S HOSPITAL   (United States)

Author keywords

Gap junctions; Hyperexcitability; Pannexin; Rasmussen encephalitis

Indexed keywords

BIOCYTIN; CALCIUM BINDING PROTEIN; CONNEXIN 36; PROTEIN; PROTEIN IBA1; UNCLASSIFIED DRUG; AIF1 PROTEIN, HUMAN; DNA BINDING PROTEIN; FAMPRIDINE; GAP JUNCTION PROTEIN; LYSINE; MEFLOQUINE; POTASSIUM CHANNEL BLOCKING AGENT;

ARTICLE; BRAIN ELECTROPHYSIOLOGY; CELL ACTIVATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; NEUROTRANSMISSION; PROTEIN EXPRESSION; PYRAMIDAL NERVE CELL; RASMUSSEN SYNDROME; SCHOOL CHILD; TREATMENT OUTCOME; WESTERN BLOTTING; ADOLESCENT; ANALOGS AND DERIVATIVES; BIOPHYSICS; BRAIN CORTEX; COHORT ANALYSIS; ELECTROSTIMULATION; ENCEPHALITIS; EXCITATORY POSTSYNAPTIC POTENTIAL; IN VITRO STUDY; MEMBRANE POTENTIAL; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATCH CLAMP TECHNIQUE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

4-AMINOPYRIDINE; ADOLESCENT; BIOPHYSICS; CEREBRAL CORTEX; CHILD; COHORT STUDIES; CONNEXINS; DNA-BINDING PROTEINS; ELECTRIC STIMULATION; ENCEPHALITIS; EXCITATORY POSTSYNAPTIC POTENTIALS; FEMALE; HUMANS; IN VITRO TECHNIQUES; LYSINE; MAGNETIC RESONANCE IMAGING; MALE; MEFLOQUINE; MEMBRANE POTENTIALS; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; PYRAMIDAL CELLS;

EID: 84921549251     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12352     Document Type: Article

References (59)

1. Hart YM, Cortez M, Andermann F, et al. Medical treatment of Rasmussen's syndrome (chronic encephalitis and epilepsy): effect of high-dose steroids or immunoglobulins in 19 patients. Neurology 1994;44:1030-1036.
2. Granata T. Rasmussen's syndrome. Neurol Sci 2003;24(Suppl 4):S239-S243.
3. Andrews PI, McNamara JO. Rasmussen's encephalitis: an autoimmune disorder? Curr Opin Neurol 1996;9:141-145.
4. Bien CG, Bauer J. T-cells in human encephalitis. Neuromolecular Med 2005;7:243-253.
5. Oguni H, Andermann F, Rasmussen T. The Natural History of the Syndrome of Chronic Encephalitis and Epilepsy: A Study of the MNI Series of Forty-eight Cases. In: Andermann F, editor. Chronic Encephalitis and Epilepsy Rasmussen's Syndrome. USA: Butterworth-Heinemann, 1991;7-35.
6. Varadkar S, Bien CG, Kruse CA, et al. Rasmussen's encephalitis: clinical features, pathobiology, and treatment advances. Lancet Neurol 2014;13:195-205.
7. Bien CG, Urbach H, Deckert M, et al. Diagnosis and staging of Rasmussen's encephalitis by serial MRI and histopathology. Neurology 2002;58:250-257.
8. Nabbout R. Autoimmune and inflammatory epilepsies. Epilepsia 2012;53(Suppl 4):58-62.
9. Farrell MA, Droogan O, Secor DL, Poukens V, Quinn B, Vinters HV. Chronic encephalitis associated with epilepsy: immunohistochemical and ultrastructural studies. Acta Neuropathol 1995;89:313-321.
10. Farrell MA, Cheng L, Cornford ME, Grody WW, Vinters HV. Cytomegalovirus and Rasmussen's encephalitis. Lancet 1991;337:1551-1552.
11. Vinters HV, Wang R, Wiley CA. Herpesviruses in chronic encephalitis associated with intractable childhood epilepsy. Hum Pathol 1993;24:871-879.
12. Rogers SW, Andrews PI, Gahring LC, et al. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science 1994;265:648-651.
13. Takahashi Y, Mori H, Mishina M, et al. Autoantibodies and cell-mediated autoimmunity to NMDA-type GluRepsilon2 in patients with Rasmussen's encephalitis and chronic progressive epilepsia partialis continua. Epilepsia 2005;46(Suppl 5):152-158.
14. He XP, Patel M, Whitney KD, Janumpalli S, Tenner A, McNamara JO. Glutamate receptor GluR3 antibodies and death of cortical cells. Neuron 1998;20:153-163.
15. Twyman RE, Gahring LC, Spiess J, Rogers SW. Glutamate receptor antibodies activate a subset of receptors and reveal an agonist binding site. Neuron 1995;14:755-762.
16. Mantegazza R, Bernasconi P, Baggi F, et al. Antibodies against GluR3 peptides are not specific for Rasmussen's encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures. J Neuroimmunol 2002;131:179-185.
17. Watson R, Jiang Y, Bermudez I, et al. Absence of antibodies to glutamate receptor type 3 (GluR3) in Rasmussen encephalitis. Neurology 2004;63:43-50.
18. Wiendl H, Bien CG, Bernasconi P, et al. GluR3 antibodies: prevalence in focal epilepsy but no specificity for Rasmussen's encephalitis. Neurology 2001;57:1511-1514.
19. Trippe J, Steinke K, Orth A, Faustmann PM, Hollmann M, Haase CG. Autoantibodies to glutamate receptor antigens in multiple sclerosis and Rasmussen's encephalitis. NeuroImmunoModulation 2014;21:189-194.
20. Harvey AS, Cross JH, Shinnar S, Mathern GW, Taskforce IPESS. Defining the spectrum of international practice in pediatric epilepsy surgery patients. Epilepsia 2008;49:146-155.
21. Cepeda C, Hurst RS, Flores-Hernandez J, et al. Morphological and electrophysiological characterization of abnormal cell types in pediatric cortical dysplasia. J Neurosci Res 2003;72:472-486.
22. Blumcke I, Thom M, Aronica E, et al. The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission. Epilepsia 2011;52:158-174.
23. Cepeda C, Andre VM, Levine MS, et al. Epileptogenesis in pediatric cortical dysplasia: the dysmature cerebral developmental hypothesis. Epilepsy Behav 2006;9:219-235.
24. Hemb M, Velasco TR, Parnes MS, et al. Improved outcomes in pediatric epilepsy surgery: the UCLA experience, 1986-2008. Neurology 2010;74:1768-1775.
25. Salamon N, Kung J, Shaw SJ, et al. FDG-PET/MRI coregistration improves detection of cortical dysplasia in patients with epilepsy. Neurology 2008;71:1594-1601.
26. Wirenfeldt M, Clare R, Tung S, Bottini A, Mathern GW, Vinters HV. Increased activation of Iba1 + microglia in pediatric epilepsy patients with Rasmussen's encephalitis compared with cortical dysplasia and tuberous sclerosis complex. Neurobiol Dis 2009;34:432-440.
27. Cepeda C, Walsh JP, Peacock W, Buchwald NA, Levine MS. Dye-coupling in human neocortical tissue resected from children with intractable epilepsy. Cereb Cortex 1993;3:95-107.
28. Avoli M, Mattia D, Olivier A. A window on the physiopathogenesis of seizures in patients with cortical dysplasia. Adv Exp Med Biol 2002;497:123-132.
29. Mattia D, Olivier A, Avoli M. Seizure-like discharges recorded in human dysplastic neocortex maintained in vitro. Neurology 1995;45:1391-1395.
30. Gigout S, Louvel J, Kawasaki H, et al. Effects of gap junction blockers on human neocortical synchronization. Neurobiol Dis 2006;22:496-508.
31. Devinsky O, Vezzani A, Najjar S, De Lanerolle NC, Rogawski MA. Glia and epilepsy: excitability and inflammation. Trends Neurosci 2013;36:174-184.
32. Aronica E, Crino PB. Inflammation in epilepsy: clinical observations. Epilepsia 2011;52(Suppl 3):26-32.
33. Vezzani A, Friedman A, Dingledine RJ. The role of inflammation in epileptogenesis. Neuropharmacology 2013;69:16-24.
34. Levite M, Fleidervish IA, Schwarz A, Pelled D, Futerman AH. Autoantibodies to the glutamate receptor kill neurons via activation of the receptor ion channel. J Autoimmun 1999;13:61-72.
35. Kielian T. Glial connexins and gap junctions in CNS inflammation and disease. J Neurochem 2008;106:1000-1016.
36. Carlen PL. Curious and contradictory roles of glial connexins and pannexins in epilepsy. Brain Res 2012;1487:54-60.
37. Retamal MA, Froger N, Palacios-Prado N, et al. Cx43 hemichannels and gap junction channels in astrocytes are regulated oppositely by proinflammatory cytokines released from activated microglia. J Neurosci 2007;27:13781-13792.
38. Bennett MV, Garre JM, Orellana JA, Bukauskas FF, Nedergaard M, Saez JC. Connexin and pannexin hemichannels in inflammatory responses of glia and neurons. Brain Res 2012;1487:3-15.
39. Ma W, Hui H, Pelegrin P, Surprenant A. Pharmacological characterization of pannexin-1 currents expressed in mammalian cells. J Pharmacol Exp Ther 2009;328:409-418.
40. MacVicar BA, Thompson RJ. Non-junction functions of pannexin-1 channels. Trends Neurosci 2010;33:93-102.
41. Dahl G, Harris AL. Pannexins or Connexins? In: Harris AL, Locke D, editors. Connexins: A Guide. New York, USA: Humana Press, 2009;287-301.
42. Eugenin EA, Basilio D, Saez JC, et al. The role of gap junction channels during physiologic and pathologic conditions of the human central nervous system. J Neuroimmune Pharmacol 2012;7:499-518.
43. Collignon F, Wetjen NM, Cohen-Gadol AA, et al. Altered expression of connexin subtypes in mesial temporal lobe epilepsy in humans. J Neurosurg 2006;105:77-87.
44. Garbelli R, Frassoni C, Condorelli DF, et al. Expression of connexin 43 in the human epileptic and drug-resistant cerebral cortex. Neurology 2011;76:895-902.
45. Shestopalov VI, Panchin Y. Pannexins and gap junction protein diversity. Cell Mol Life Sci 2008;65:376-394.
46. Eugenin EA, Eckardt D, Theis M, Willecke K, Bennett MV, Saez JC. Microglia at brain stab wounds express connexin 43 and in vitro form functional gap junctions after treatment with interferon-gamma and tumor necrosis factor-alpha. Proc Natl Acad Sci U S A 2001;98:4190-4195.
47. Dobrenis K, Chang HY, Pina-Benabou MH, et al. Human and mouse microglia express connexin36, and functional gap junctions are formed between rodent microglia and neurons. J Neurosci Res 2005;82:306-315.
48. Ohmori I, Ouchida M, Kobayashi K, et al. Rasmussen encephalitis associated with SCN 1 A mutation. Epilepsia 2008;49:521-526.
49. Manning TJ Jr, Sontheimer H. Spontaneous intracellular calcium oscillations in cortical astrocytes from a patient with intractable childhood epilepsy (Rasmussen's encephalitis). Glia 1997;21:332-337.
50. Bernasconi P, Cipelletti B, Passerini L, et al. Similar binding to glutamate receptors by Rasmussen and partial epilepsy patients' sera. Neurology 2002;59:1998-2001.
51. Gibbs JW 3rd, Morton LD, Amaker B, Ward JD, Holloway KL, Coulter DA. Physiological analysis of Rasmussen's encephalitis: patch clamp recordings of altered inhibitory neurotransmitter function in resected frontal cortical tissue. Epilepsy Res 1998;31:13-27.
52. Whitney KD, McNamara JO. GluR3 autoantibodies destroy neural cells in a complement-dependent manner modulated by complement regulatory proteins. J Neurosci 2000;20:7307-7316.
53. Bauer J, Elger CE, Hans VH, et al. Astrocytes are a specific immunological target in Rasmussen's encephalitis. Ann Neurol 2007;62:67-80.
54. Orellana JA, Froger N, Ezan P, et al. ATP and glutamate released via astroglial connexin 43 hemichannels mediate neuronal death through activation of pannexin 1 hemichannels. J Neurochem 2011;118:826-840.
55. Thompson RJ, Macvicar BA. Connexin and pannexin hemichannels of neurons and astrocytes. Channels (Austin) 2008;2:81-86.
56. Dvoriantchikova G, Ivanov D, Barakat D, et al. Genetic ablation of Pannexin1 protects retinal neurons from ischemic injury. PLoS ONE 2012;7:e31991.
57. Hormuzdi SG, Pais I, LeBeau FE, et al. Impaired electrical signaling disrupts gamma frequency oscillations in connexin 36-deficient mice. Neuron 2001;31:487-495.
58. Maier N, Guldenagel M, Sohl G, Siegmund H, Willecke K, Draguhn A. Reduction of high-frequency network oscillations (ripples) and pathological network discharges in hippocampal slices from connexin 36-deficient mice. J Physiol 2002;541:521-528.
59. Thompson RJ, Jackson MF, Olah ME, et al. Activation of pannexin-1 hemichannels augments aberrant bursting in the hippocampus. Science 2008;322:1555-1559.